SCIENTURE HOLDINGS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
SCIENTURE HOLDINGS, INC. (SCNX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$13.82 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2022-03-28
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-12-31 was -$110.64K.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-09-30 was -$60.97K.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-06-30 was -$142.13K, a 222.22% decline year-over-year.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2021-03-31 was $299.92K, a 122.65% increase year-over-year.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2021 was -$13.82K, a 111.48% decline from fiscal 2020.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2020 was $120.40K.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2019 was -$8.99K.
- SCIENTURE HOLDINGS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2018 was -$18.79K.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$110.64K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$171.61K derived: sum of 2 quarters · filed 2022-03-28 | -$313.74K derived: sum of 3 quarters · filed 2022-03-28 | -$13.82K 10-K · filed 2022-03-28 |
| 2021-09-30 | -$60.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | -$203.10K derived: sum of 2 quarters · filed 2021-10-25 | $96.83K 10-Q · filed 2021-10-25 | $29.94K derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-06-30 | -$142.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-26 | $157.79K 10-Q · filed 2021-07-26 | $90.90K derived: sum of 3 quarters · filed 2022-03-28 | $27.20K derived: sum of 4 quarters · filed 2022-03-28 |
| 2021-03-31 | $299.92K 10-Q · filed 2021-04-26 | $233.03K derived: sum of 2 quarters · filed 2022-03-28 | $169.33K derived: sum of 3 quarters · filed 2022-03-28 | $285.62K derived: sum of 4 quarters · filed 2022-03-28 |
| 2020-12-31 | -$66.89K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$130.59K derived: sum of 2 quarters · filed 2022-03-28 | -$14.30K derived: sum of 3 quarters · filed 2022-03-28 | $120.40K 10-K · filed 2022-03-28 |
| 2020-09-30 | -$63.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-25 | $52.59K derived: sum of 2 quarters · filed 2021-10-25 | $187.29K 10-Q · filed 2021-10-25 | $135.05K derived: sum of 4 quarters · filed 2021-10-25 |
| 2020-06-30 | $116.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-26 | $251.00K 10-Q · filed 2021-07-26 | $198.75K derived: sum of 3 quarters · filed 2021-07-26 | $248.66K derived: sum of 4 quarters · filed 2021-07-26 |
| 2020-03-31 | $134.71K 10-Q · filed 2021-04-26 | $82.46K derived: sum of 2 quarters · filed 2021-04-26 | $132.37K derived: sum of 3 quarters · filed 2021-04-26 | $95.95K derived: sum of 4 quarters · filed 2021-04-26 |
| 2019-12-31 | -$52.24K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$2.34K derived: sum of 2 quarters · filed 2021-03-29 | -$38.76K derived: sum of 3 quarters · filed 2021-03-29 | -$8.99K 10-K · filed 2021-03-29 |
| 2019-09-30 | $49.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | $13.49K derived: sum of 2 quarters · filed 2020-10-26 | $43.26K 10-Q · filed 2020-10-26 | -$73.60K derived: sum of 4 quarters · filed 2020-10-26 |
| 2019-06-30 | -$36.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | -$6.65K 10-Q · filed 2020-07-27 | -$123.50K derived: sum of 3 quarters · filed 2020-07-27 | |
| 2019-03-31 | $29.77K 10-Q · filed 2020-05-04 | -$87.08K derived: sum of 2 quarters · filed 2020-05-04 | ||
| 2018-12-31 | -$116.85K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | -$18.79K 10-K · filed 2020-03-30 | ||
| 2018-09-30 | $98.06K 10-Q · filed 2019-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |